A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults.

Trial Profile

A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Meropenem; Metronidazole
  • Indications Bacterial infections; Intra-abdominal infections
  • Focus Therapeutic Use
  • Sponsors Novexel
  • Most Recent Events

    • 05 Jun 2017 Primary endpoint of clinical response at the TOC visit in microbiologically evaluable has not been met, according to results presented at the ASM Microbe 2017.
    • 05 Jun 2017 Results presented at the ASM Microbe 2017
    • 12 Apr 2016 Results (pooled analysis of this and other five studies, n = 2404) assessing efficacy of ceftazidime-avibactam against ceftazidime-resistant Gram-negative pathogens presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top